2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

9:00AM-10:30AM: Abstract Number: 2936

Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis

6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

9:00AM-10:30AM: Abstract Number: 2938

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial

6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

9:00AM-10:30AM: Abstract Number: 2914

Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis

6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

9:00AM-10:30AM: Abstract Number: 2925

Fatty Lesions Detected on MRI Scans in Patients with Ankylosing Spondylitis Are Based on the Deposition of Fat in the Vertebral Bone Marrow

6W011 ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Imaging of Axial SpA (2922–2927)

9:00AM-10:30AM: Abstract Number: 2943

Helping a Non-Urban Community Walk with Ease: A Feasibility Pilot Study of an Arthritis Activity Intervention

6W016 ARHP Abstract: Interventions & Self-Management–ARHP III (2940–2945)

9:00AM-10:30AM: Abstract Number: 2900

Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells

6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

9:00AM-10:30AM: Abstract Number: 2898

Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)

6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

9:00AM-10:30AM: Abstract Number: 2923

Is All MRI-SIJ Inflammation the Same? Gradient of Structural Damage with Increasing Cumulative Inflammation at the SIJ Quadrant Level in Axial Spondyloarthritis – 5-Year Data from the DESIR Cohort

6W011 ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Imaging of Axial SpA (2922–2927)

9:00AM-10:30AM: Abstract Number: 2944

Longitudinal Outcomes and Predictors of E-Learning Effectiveness in Patients with Axial Spondyloarthritis: A Randomized Controlled Trial

6W016 ARHP Abstract: Interventions & Self-Management–ARHP III (2940–2945)

9:00AM-10:30AM: Abstract Number: 2912

Lupus Flare Activity from the Patient Perspective

6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

9:00AM-10:30AM: Abstract Number: 2922

Magnetic Resonance Imaging of Sacroiliac Joints in Patients with Osteitis Condensans Ilii Reveals a Typical Pattern of Lesions Relevant for Differential Diagnosis with Axial Spondyloarthritis

6W011 ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Imaging of Axial SpA (2922–2927)

9:00AM-10:30AM: Abstract Number: 2931

Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects

6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

9:00AM-10:30AM: Abstract Number: 2917

Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis

6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

9:00AM-10:30AM: Abstract Number: 2934

Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients

6W012 ACR Abstract: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939)

9:00AM-10:30AM: Abstract Number: 2916

New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients

6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].